Sana Biotechnology Inc (SANA) concluded trading on Wednesday at a closing price of $2.92, with 7.63 million shares of worth about $22.27 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 81.37% during that period and on July 02, 2025 the price saw a gain of about 3.18%. Currently the company’s common shares owned by public are about 225.46M shares, out of which, 125.44M shares are available for trading.
Stock saw a price change of 0.69% in past 5 days and over the past one month there was a price change of 32.73%. Year-to-date (YTD), SANA shares are showing a performance of -46.52% which increased to 79.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.26 but also hit the highest price of $7.40 during that period. The average intraday trading volume for Sana Biotechnology Inc shares is 4.11 million. The stock is currently trading 6.94% above its 20-day simple moving average (SMA20), while that difference is up 30.78% for SMA50 and it goes to 7.53% higher than SMA200.
Sana Biotechnology Inc (NASDAQ: SANA) currently have 225.46M outstanding shares and institutions hold larger chunk of about 51.54% of that.
The stock has a current market capitalization of $658.62M and its 3Y-monthly beta is at 1.85. It has posted earnings per share of -$0.88 in the same period. It has Quick Ratio of 3.40 while making debt-to-equity ratio of 0.44. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SANA, volatility over the week remained 7.96% while standing at 10.84% over the month.
Analysts are in expectations that Sana Biotechnology Inc (SANA) stock would likely to be making an EPS of -0.2 in the current quarter, while forecast for next quarter EPS is -0.22 and it is -0.74 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.2 which is -0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 34.68% while it is estimated to increase by 6.84% in next year. EPS is likely to grow at an annualized rate of 14.07% for next 5-years, compared to annual growth of -10.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citizens JMP on March 18, 2025 offering a Mkt outperform rating for the stock and assigned a target price of $5 to it. Coverage by Jefferies stated Sana Biotechnology Inc (SANA) stock as a Buy in their note to investors on March 14, 2025, suggesting a price target of $7 for the stock. Stock get a Buy rating from Rodman & Renshaw on June 26, 2024.
